Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

NCT00328172 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo
DRUG: BI 1356 dose 3 once daily
DRUG: BI 1356 dose 2 once daily
DRUG: BI 1356 dose 1 once daily
DRUG: Metformin

Sponsor

Boehringer Ingelheim